Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer
AffiliationDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
MetadataShow full item record
AbstractTreatment stratification in stage IV NSCLC is guided by identification of oncogene driver mutations. Actionable mutations with current licenced therapeutic agents include epidermal growth factor receptor (EGFR), rearrangements of anaplastic lymphoma kinase (ALK), ROS-1 and BRAF V600. Alongside progress with small molecule therapy, developments in immune checkpoint inhibitors (CPIs) have transformed the landscape of stage III and stage IV NSCLC. The success of CPIs has led to evaluation with small molecule therapy in both concurrent and sequential settings. In this review we summarise recent results of combination CPIs and tyrosine kinase inhibitors (TKIs) in stage IV NSCLC, detailing significant toxicity and its potential mechanisms with both concurrent and sequential approaches. As more therapeutic targets are being discovered it is becoming increasingly important for clinicians to correctly sequence therapy for delivery of safe and effective treatment. In addition to stage IV disease we suggest that comprehensive molecular profiling of key NSCLC drivers, particularly in stage III disease, will help to inform optimal treatment sequencing and minimise potential toxicity.
CitationAdderley H, Blackhall FH, Lindsay CR. Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer. Cancer Immunol Immunother. 2020.
JournalCancer Immunology Immunotherapy
- The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
- Authors: Golding B, Luu A, Jones R, Viloria-Petit AM
- Issue date: 2018 Feb 19
- Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
- Authors: Singhi EK, Horn L, Sequist LV, Heymach J, Langer CJ
- Issue date: 2019 Jan
- Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
- Authors: Nagano T, Tachihara M, Nishimura Y
- Issue date: 2019
- Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
- Authors: Genova C, Rossi G, Tagliamento M, Rijavec E, Biello F, Cerbone L, Zullo L, Grossi F
- Issue date: 2020 Apr
- ALK inhibitors in the treatment of advanced NSCLC.
- Authors: Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F
- Issue date: 2014 Mar